Recent news on Valdecoxib

Risk of myocardial infarction associated with selective COX-2 ...  -  Apr 26, 2007
HeartZine,We found celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib were associated with higher MI risks compared against placebo.

Another coxib for arthritis? FDA panel says no  -  Apr 29, 2007
American Medical News (subscription)Two of the three drugs in that group -- Vioxx (rofecoxib) and Bextra (valdecoxib) -- were withdrawn from the market in 2004 and 2005 respectively because

FDA Says No to New Cox-2 Inhibitor  -  Apr 27, 2007
MedPage Today,The following spring Pfizer withdrew valdecoxib (Bextra) after similar reports surfaced about it. The FDA then ordered boxed warnings about cardiovascular

Ask Dr. Weil: Achy Joints  -  Apr 30, 2007
The Ledger,WEIL: A lot of people ask me this, especially since the popular arthritis drugs valdecoxib and rofecoxib were pulled from the market in 2004 and 2005.

Risk of myocardial infarction associated with selective COX-2 ...  -  26 Apr 2007
HeartZine,We found celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib were associated with higher MI risks compared against placebo.

Pharma firms face ban on Merck generic  -  Apr 15, 2007
Business Standard,Trade sources said the pain management drug market in India is valued over Rs 1500 crore and the banned valdecoxib alone had a market of Rs 80-100 crore.

Merck generic drug face ban  -  Apr 15, 2007
Andhra Cafe,Of the Cox II drugs, which include etoricoxib, celecoxib, valdecoxib and parecoxib, two drugs - rofecoxib (Merck’s Vioxx) and valdecoxib (Pfizer’s Bextra)

FDA Advisers Give Overwhelming Rejection to Etoricoxib (Arcoxia)  -  Apr 12, 2007
MedPage Today,The following spring Pfizer withdrew valdecoxib (Bextra) after similar reports surfaced about it. The FDA then ordered boxed warnings about cardiovascular

Consumer group asks FDA to ban Pfizer's new Celebrex ad  -  Apr 10, 2007
Pharma Times (subscription),...request by the agency at a time when Merck & Co's COX-2 inhibitor Vioxx (rofecoxib) and Pfizer's own Bextra (valdecoxib) were withdrawn from the market.

Ease aching body with right medicine  -  Apr 2, 2007
Denver Post,The COX-2 inhibitors-celecoxib (Celebrex), rofecoxib (Vioxx), valdecoxib (Bextra)-were supposed to be the better NSAIDs, a new generation of medications

Europe extends label on Pfizer's Celebrex  -  Feb 23, 2007
Pharma Times (subscription),...association with serious cardiovascular side-effects that led to the withdrawal of Merck & Co's Vioxx (rofecoxib) and Pfizer's own Bextra (valdecoxib).

Nicholas Piramal consolidated net at Rs 55.5 crore  -  18 Jan 2007
Economic Times,Lower sales of its cough syrup Phensedyl, withdrawal of two Valdecoxib brands — Vah/Valto, in which the company was a market leader, and a marked-to-market

The Role of Litigation in Defining Drug Risks  -  Jan 16, 2007
Journal of American Medical Association (subscription),For example, the selective cyclooxygenase inhibitor valdecoxib was submitted for approval in 2001 for treatment of dysmenorrhea, osteoarthritis,

Selective and Nonselective Cyclooxygenase-2 Inhibitors and ...  -  Jan 2, 2007
Journal of Bone and Joint Surgery (subscription)Results: When healing was assessed at twenty-one days, the seven-day treatment produced only a trend for a higher rate of nonunion in valdecoxib and

BUY FIORICET, Cheap Fioricet, Fioricet Online  -  Dec 25, 2006
Indymedia Colombia,To reduce dizzy or buy fioricet Using valdecoxib with these medicines may be absolutely sure that ambien best for you. It is ambien to allow for an ambien

FDA Proposes Labeling Changes to Over-the-Counter Pain Relievers  -  Dec 20, 2006
SeniorJournal.com,September 12, 2006 – Although two COX-2 inhibitors have already been withdrawn from the market: rofecoxib (Vioxx) and valdecoxib (Bextra), the evidence

BUY FIORICET, Cheap Fioricet, Fioricet Online  -  Dec 25, 2006
Indymedia Colombia,To reduce dizzy or buy fioricet Using valdecoxib with these medicines may be absolutely sure that ambien best for you. It is ambien to allow for an ambien

FDA Proposes Labeling Changes to Over-the-Counter Pain Relievers  -  Dec 20, 2006
SeniorJournal.com,September 12, 2006 – Although two COX-2 inhibitors have already been withdrawn from the market: rofecoxib (Vioxx) and valdecoxib (Bextra), the evidence

Celebrex Gets FDA Okay for Juvenile Rheumatoid Arthritis  -  Dec 15, 2006
MedPage Today,Bextra (valdecoxib), a Cox-2 drug marketed by Pfizer, was withdrawn in the first quarter of 2005 when it, too, was linked to increased risk of

New evidence on risks associated with Cox-2 inhibitors and NSAIDs  Oct 21, 2006
...risk. Two COX-2 inhibitors have already been withdrawn from the market: Rofecoxib ( Vioxx ) and Valdecoxib ( Bextra ). Jingjing ... -Xagena.it, Heart Attack Risks, Pain Relief Similar for Most Osteoarthritis ...  Oct 14, 2006
Two COX-2 inhibitors—rofecoxib (Vioxx) and valdecoxib (Bextra)—were voluntarily withdrawn from the market because of heart attack risks. ... -Community Dispatch (press release) Analgesic Efficacy of Valdecoxib for Acute Postoperative Pain ...  Sep 20, 2006
Richard Pollak, DPM, MS * , Gary A. Raymond, DPM , Richard M. Jay, DPM , Howard J. Hillstrom, PhD , Kieran T. Mahan, DPM, MS , Dennis Riff, MD , Ellis L. Jacobs ... -Journal of the American Podiatric Medical Association (subscription)

Buy Nicholas Piramal with target of Rs 268: P-sec  Sep 18, 2006
Lower growth in the bottomline was mainly because of Avecia loss and poor growth in domestic formulations business on account of Valdecoxib and VAT effects. ... -Moneycontrol.com

COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk  Sep 12, 2006
Against this backdrop, public concern was heightened by announcements that celecoxib, valdecoxib, and naproxen might also increase MI risk. ... -Journal of American Medical Association (subscription)

Latest studies reveal more risks with Vioxx  Sep 18, 2006
...corporate profitability. COX-2 inhibitors, Vioxx and Valdecoxib (Bextra), have already been withdrawn from the market. Merck has ... -News-Medical.net

Journal of the American Podiatric Medical Association  Sep 20, 2006
Such modalities included low-Dye rest dressings, oral anti-inflammatory medications (valdecoxib, rofecoxib, and celecoxib), and 1% lidocaine/corticosteroid ... -Journal of the American Podiatric Medical Association (subscription)

Old, 'safe' painkillers found to cause same heart ills as new  Sep 13, 2006
Zhang of Harvard Medical School in Boston, looked at the safety of cyclooxygenase 2 (cox-2) inhibitors such as Vioxx, Celebrex and valdecoxib (brand name Bextra ... -Globe and Mail

More Evidence of Risk Found for Vioxx  Sep 12, 2006
...with controls. The FDA-approved agents studied in the Harvard meta-analysis included Vioxx, Celebrex , and Bextra (valdecoxib). Of ... -MedPage Today

New class of super NSAIDs  Sep 12, 2006
...suppression of prostacyclin - explains the risk of heart attacks from NSAIDs that inhibit COX-2, such as rofecoxib (Vioxx), valdecoxib (Bextra), and celecoxib ... -News-Medical.net

Naproxen Has Few Risks Compared To Other Painkillers  Sep 13, 2006
Two COX-2 inhibitors have already been withdrawn from the market: rofecoxib (marketed as Vioxx) and valdecoxib (marketed as Bextra). -E Canada Now

JAMA Releases Early Reports Finding Increased Heart, Kidney Risks ...  Sep 12, 2006
September 12, 2006 – Although two COX-2 inhibitors have already been withdrawn from the market: rofecoxib (Vioxx) and valdecoxib (Bextra), the evidence ... -SeniorJournal.com

Dangers of Common Drugs  Sep 12, 2006
The new research backs up previous findings that led the FDA to pull two COX-2 inhibitors, rofecoxib (Vioxx) and valdecoxib (Bextra), from the market. ... -Ivanhoe

New studies add to painkiller controversy  Sep 13, 2006
...on patient safety rather than corporate profitability, and, ultimately, common sense will prevail." Two COX-2 inhibitors, Vioxx and valdecoxib (Bextra), have ... -Pharma Times (subscription)

Advisers Ask FDA to Approve Celebrex for Juvenile Rheumatoid Arthritis  -  Nov 30, 2006
MedPage Today,Bextra (valdecoxib), a Cox-2 drug marketed by Pfizer, was withdrawn in the first quarter of 2005 when it, too, was linked to increased risk of

Know Your Medicine - Medicines can be toxic too  -  Nov 21, 2006
Newindpress (subscription),A recent example is withdrawal of valdecoxib, an anti-inflammatory agent, from the world market. The doctors, health care professionals and patients should

IDEA AG receives approvable letter from Swissmedic for IDEA-033, a ...  -  Nov 16, 2006
PipelineReview.com (press release),However, as illustrated by recent world-wide withdrawals of Vioxx® (rofecoxib) and Bextra® (valdecoxib), COX-2 inhibitors can lead to serious adverse side

AHA: Arcoxia (etoricoxib) May Not Increase Risk of Cardiovascular ...  -  Nov 13, 2006
MedPage Today,Moreover, the Vioxx episode triggered additional scrutiny of Celebrex (celecoxib) and Bextra (valdecoxib) as well as all NSAIDs. As a result, Bextra,

Research Summary: Rheumatoid Arthritis  Aug 18, 2006
...pain. These are medications such as aspirin, ibuprofen, indomethacin and COX-2 inhibitors such as valdecoxib and celecoxib. Analgesic ... -abc7news.com

Panacea Biotec Obtains Patent For Extended Release Pharmaceutical ...  Aug 6, 2006
Between 2000-2005, NSAIDs categorized as Coxibs (Celecoxib, Rofecoxib, Valdecoxib, Etoricoxib) were the most preferred NSAIDs in management of Osteoarthritis. ... -Trading Markets

Panacea Biotec obtains patent for Nimesulide  Aug 7, 2006
Many NSAIDs categorized as Coxibs (Celecoxib, Rofecoxib, Valdecoxib, Etoricoxib), most preferred NSAIDs, had been withdrawn between 2000-2005. ... -Myiris.com

Panacea Biotec granted patent for 'controlled release' nimesulide  Aug 7, 2006
Between 2000-2005, NSAIDs categorised as coxibs (celecoxib, rofecoxib, valdecoxib, etoricoxib) were the most preferred NSAIDs in managing osteoarthritis. ... -domain-B

COX-2 Inhibitors Prescribed To Reduce Gastrointestinal Toxicity ...  Jul 30, 2006
Spurred by these findings and other safety concerns, 2 of the 3 FDA-approved coxibs - rofecoxib, known to consumers as Vioxx, and valdecoxib, known to ... -Medical News Today

Cardax Pharmaceuticals: Astaxanthin Eliminates Adverse Effects of ...  Jun 28, 2006
This reactive metabolite could not be derived from other COX-2 selective agents, including celecoxib (Celebrex), valdecoxib, and lumaricoxib, due to ... -Genetic Engineering News



Glenmark: Study in contrast  17 May 2006
API prices. Also, the discontinuation of Valdecoxib (medication for osteoarthritis) earlier this year affected top line. However ... - Business Standard

How safe is your painkiller?  May 13, 2006
While valdecoxib and rofecoxib have been voluntarily withdrawn from the US market by the manufacturers, mandatory celecoxib labelling is required to contain ... - Hindustan Times

Vioxx's risk high in first two weeks, study finds  May 3, 2006
Research has shown that Celebrex does not appear to increase cardiovascular risk in the same way as Vioxx and Bextra (valdecoxib), which was pulled from the ... - Globe and Mail

Use of First- and Second-Generation Cyclooxygenase-2-Selective ...  Apr 19, 2006
Whether the newer second-generation COX-2 inhibitors (etoricoxib, valdecoxib) also increase the cardiovascular risk is unknown. ... - HeartZine

Despite Conflicts, Drug Judges Continue to Vote Yea or Nay  Apr 26, 2006
They noted that at a 2005 advisory committee meeting to evaluate the risks of the COX-2 inhibitors Bextra (valdecoxib), Celebrex (celecoxib) and Vioxx ... - MedPage Today

Selective inhibitors of mPGES-1, a new class of anti-inflammatory ...  Apr 17, 2006
Ever since the association of selective inhibitors of COX-2 – Vioxx ( Rofecoxib ), Bextra ( Valdecoxib ), and Celebrex ( Celecoxib ) - with an increased ... - Xagena.it

Cardiovascular outcomes in new users of coxibs and nonsteroidal ...  Apr 29, 2006
Predefined exposure groups included the 3 coxibs available in the US during the study period (celecoxib, rofecoxib, and valdecoxib), as well as oral ... - HeartZine

Pfizer profits soar despite slipping revenues  Apr 20, 2006
...the first quarter of 2005 had been impacted by charges related to the withdrawal from the marketplace of COX-2 inhibitor Bextra (valdecoxib) and repatriation ... - Pharma Times (subscription)





Proprius gets rights to AlphaRx's Indaflex  11 Apr 2006
..."Given the adverse event profiles of oral NSAIDs and COX-2 inhibitors, and the withdrawals of rofecoxib and valdecoxib from the market, we believe Indaflex has ... - United Press International

New advertising code of conduct established in Vioxx withdrawal ...  Mar 9, 2006
...celecoxib) and led to a review of the safety of all the COX-II inhibitors, resulting in the removal of Pfizer's other product, Bextra (valdecoxib), from the ... - Pharmaceutical Business Review



Safety of Cox-2 Selective Nonsteroidal Antiinflammatory Drugs for ...  Feb 14, 2006
As stated in the editorial (1), the perioperative use of parecoxib-valdecoxib over a period of 14 days in patients undergoing cardiac surgery produced some ... - Anesthesia & Analgesia (subscription),

Meta-Analysis Links Celebrex to Doubling of MI Risk  Mar 2, 2006
Pfizer followed by withdrawing Bextra (valdecoxib) on April 7, 2005, a day after the FDA announced that it was adding a black box warning to the labels of all ... - MedPage Today,

Date set for first Celebrex trial  Feb 28, 2006
Soon after, Pfizer was asked to remove its COX-2 inhibitor Bextra (valdecoxib) from the market on safety concerns, but Celebrex has been allowed to remain on ... - Pharma Times (subscription),

PFIZER INC.: FDA: Bextra side effects are `potentially' life ...  Feb 9, 2006
Pfizer officials in May said they hoped to resume selling the drug, also known as valdecoxib. "In the absence of any demonstrated ... - Chicago Tribune,

Celebrex Gets Passing Grades for Gastric and Cardiac Safety  Feb 23, 2006
A year ago, Bextra (valdecoxib), another Cox-2 inhibitor, was also withdrawn amid reports that it, too, increased the risk of heart attack and stroke. ... - MedPage Today,

PFIZER INC.: FDA: Bextra side effects are `potentially' life ...  09 Feb 2006
Pfizer officials in May said they hoped to resume selling the drug, also known as valdecoxib. "In the absence of any demonstrated ... - Chicago Tribune

Exports breath life into pharma in Q3  Feb 8, 2006
However, the company suffered a setbacks in the domestic market with lower sales of Phensedyl and withdrawal of two Valdecoxib brands — Vah/Valto, in which ... - Economic Times

Safety of Cox-2 Selective Nonsteroidal Antiinflammatory Drugs for ...  Jan 29, 2006
The editorial further notes that parecoxib, the injectable prodrug of the now-withdrawn valdecoxib (Bextra®; Pfizer, New York, NY), has been "widely ... - Anesthesia & Analgesia (subscription)

Nicholas Piramal Q3 net down 70%  Jan 19, 2006
Lower sales of Phensedyl and the absence of sales from two Valdecoxib brands - Vah/Valto (arthritis drugs that had contributed to NPIL's bottomline in the ... - Sify

Drug Commonly Used in Surgery Doubles Risk of Kidney Failure  Jan 26, 2006
In 2003, IREF- McSPI reported for the first time that the COX-2 inhibitor, Bextra (valdecoxib, parecoxib), was associated with stroke and impaired wound healing ... - SeniorJournal.com

Better Fix for Rheumatoid Arthritis  Feb 1, 2006
...pain. These are medications such as aspirin, ibuprofen, indomethacin and COX-2 inhibitors such as valdecoxib and celecoxib. Analgesic ... - ABC7Chicago.com

Nicholas Piramal Q3 net down 69.9%  Jan 20, 2006
The company stated that the lower sales of its leading brand, Phensedyl, and withdrawal of two valdecoxib brands, Vah and Valto, in which the company was a ... - Business Standard

Better Fix for Rheumatoid Arthritis  Jan 19, 2006
These are medications such as aspirin, ibuprofen, indomethacin and COX-2 inhibitors such as valdecoxib (BEXTRA) and celecoxib (Celebrex). ... - News 14 Carolina

Nicholas Piramal reports audited Q3 FY2006 results; Sales up 9.2% ...  Jan 20, 2006
Lower Sales of Phensedyl and withdrawal of two Valdecoxib brands – Vah/Valto, in which NPIL was a leader, affected the third quarter profitability. ... - Biotech Intelligence

Critical Information Regarding Bextra Side Effects Available ...  Jan 9, 2006
..."Bextra is the trade name for the pharmaceutical valdecoxib that was created by GD Searle & Company to combat pain suffered by those with rheumatoid and ... - Open PR

Generics bite into Pfizer's 4Q figures  Jan 20, 2006
Meanwhile, the withdrawal of COX-2 inhibitor Bextra (valdecoxib) on safety concerns and pressure on related drug Celebrex (celecoxib) continued to weigh heavy ... - Pharma Times (subscription)

COX-2 blocker Prexige launched in first EU market  Jan 17, 2006
After Pfizer's Bextra (valdecoxib) went the same way as Vioxx, Novartis decided to hold off launching Prexige (lumiracoxib), while it carried out additional ... - Pharma Times (subscription)

Arthritis patients have new hope  Jan 19, 2006
These are medications such as aspirin, ibuprofen, indomethacin and COX-2 inhibitors such as valdecoxib (BEXTRA) and celecoxib (Celebrex). ... - News 14 Charlotte

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional